Literature DB >> 21029960

Vaccine adjuvants: putting innate immunity to work.

Robert L Coffman1, Alan Sher, Robert A Seder.   

Abstract

Adjuvants enhance immunity to vaccines and experimental antigens by a variety of mechanisms. In the past decade, many receptors and signaling pathways in the innate immune system have been defined and these innate responses strongly influence the adaptive immune response. The focus of this review is to delineate the innate mechanisms by which adjuvants mediate their effects. We highlight how adjuvants can be used to influence the magnitude and alter the quality of the adaptive response in order to provide maximum protection against specific pathogens. Despite the impressive success of currently approved adjuvants for generating immunity to viral and bacterial infections, there remains a need for improved adjuvants that enhance protective antibody responses, especially in populations that respond poorly to current vaccines. However, the larger challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant vaccine antigens.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029960      PMCID: PMC3420356          DOI: 10.1016/j.immuni.2010.10.002

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  115 in total

1.  Both radioresistant and hemopoietic cells promote innate and adaptive immune responses to flagellin.

Authors:  Catherine J Sanders; Daniel A Moore; Ifor R Williams; Andrew T Gewirtz
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

2.  Vaccine adjuvants alter TCR-based selection thresholds.

Authors:  Laurent Malherbe; Linda Mark; Nicolas Fazilleau; Louise J McHeyzer-Williams; Michael G McHeyzer-Williams
Journal:  Immunity       Date:  2008-05-01       Impact factor: 31.745

3.  The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation.

Authors:  Tobias Haas; Jochen Metzger; Frank Schmitz; Antje Heit; Thomas Müller; Eicke Latz; Hermann Wagner
Journal:  Immunity       Date:  2008-03       Impact factor: 31.745

4.  Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

Authors:  Pierre Vandepapelière; Yves Horsmans; Philippe Moris; Marcelle Van Mechelen; Michel Janssens; Marguerite Koutsoukos; Pascale Van Belle; Frédéric Clement; Emmanuel Hanon; Martine Wettendorff; Nathalie Garçon; Geert Leroux-Roels
Journal:  Vaccine       Date:  2008-01-14       Impact factor: 3.641

Review 5.  Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients.

Authors:  Jiri Beran
Journal:  Expert Opin Biol Ther       Date:  2008-02       Impact factor: 4.388

6.  The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells.

Authors:  Anja Seubert; Elisabetta Monaci; Mariagrazia Pizza; Derek T O'Hagan; Andreas Wack
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

7.  The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.

Authors:  Christine Trumpfheller; Marina Caskey; Godwin Nchinda; Maria Paula Longhi; Olga Mizenina; Yaoxing Huang; Sarah J Schlesinger; Marco Colonna; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-06       Impact factor: 11.205

8.  Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5.

Authors:  Hiroki Kato; Osamu Takeuchi; Eriko Mikamo-Satoh; Reiko Hirai; Tomoji Kawai; Kazufumi Matsushita; Akane Hiiragi; Terence S Dermody; Takashi Fujita; Shizuo Akira
Journal:  J Exp Med       Date:  2008-07-07       Impact factor: 14.307

9.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants.

Authors:  Stephanie C Eisenbarth; Oscar R Colegio; William O'Connor; Fayyaz S Sutterwala; Richard A Flavell
Journal:  Nature       Date:  2008-05-21       Impact factor: 49.962

10.  Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells.

Authors:  Mirjam Kool; Thomas Soullié; Menno van Nimwegen; Monique A M Willart; Femke Muskens; Steffen Jung; Henk C Hoogsteden; Hamida Hammad; Bart N Lambrecht
Journal:  J Exp Med       Date:  2008-03-24       Impact factor: 14.307

View more
  624 in total

Review 1.  The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA.

Authors:  Neeraj K Surana; Dennis L Kasper
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

3.  Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates.

Authors:  Marcin Kwissa; Helder I Nakaya; Herold Oluoch; Bali Pulendran
Journal:  Blood       Date:  2012-01-12       Impact factor: 22.113

4.  Reorienting our view of particle-based adjuvants for subunit vaccines.

Authors:  Steven R Little
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 5.  Adjuvants for human vaccines.

Authors:  Carl R Alving; Kristina K Peachman; Mangala Rao; Steven G Reed
Journal:  Curr Opin Immunol       Date:  2012-04-19       Impact factor: 7.486

Review 6.  Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.

Authors:  Christophe J Desmet; Ken J Ishii
Journal:  Nat Rev Immunol       Date:  2012-06-22       Impact factor: 53.106

Review 7.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

8.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

9.  Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.

Authors:  Daniel Carapau; Robert Mitchell; Adéla Nacer; Alan Shaw; Caroline Othoro; Ute Frevert; Elizabeth Nardin
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

10.  Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer.

Authors:  Joseph P Nkolola; Ann Cheung; James R Perry; Darrick Carter; Steve Reed; Hanneke Schuitemaker; Maria Grazia Pau; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  Vaccine       Date:  2014-02-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.